To mitigate Fc-mediatedchallenges, we engineered 2A10-VH-Fc mutantsby introducing GRLR and LALAPG mutations to eliminate FcγR binding,thereby minimizing immune clearance and enhancing tumor targeting., Both mutants displayed significant improvement in distribution comparedwith wild-type, showing significantly reduced liver and spleen uptake,consistent with prior Fc-blocking studies linking FcγR interactionsto enhance hepatic and splenic sequestration. Here, FCGR2A is linked to neoplasm.